MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-03-2026
Aytu BioScience Depreciation & Amortization 2011-2026 | AYTU
Annual Depreciation & Amortization Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 6.72 M | 8.82 M | 10.1 M | 9.2 M | 5.71 M | 2.73 M | 2.59 M | 4.36 M | 875 K | 118 K | 97.5 K | 58.4 K | 53.4 K | 6.76 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 6.76 K | 3.79 M |
Quarterly Depreciation & Amortization Aytu BioScience
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 K | 803 K | - | 100 K | 100 K | 1.33 M | - | 200 K | 300 K | 924 K | - | 1.84 M | 1.85 M | 2.3 M | 4.5 M | 500 K | 400 K | 2.68 M | 5.35 M | 68 K | 18 K | 2.04 M | 4.01 M | 2.09 M | 16 K | 869 K | 2.16 M | 869 K | 16 K | 557 K | 1.23 M | 557 K | 329 K | 653 K | 1.32 M | 653 K | 26 K | 822 K | 1.72 M | 822 K | 12 K | 129 K | 242 K | 129 K | 1.2 K | 24.6 K | 2.39 K | - | 1.2 K | 3.75 K | 2.53 K | 1.2 K | 1.29 K | 4.79 K | 3.32 K | 1.29 K | 1.66 K | 5.1 K | 3.36 K | 1.66 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.35 M | 1.2 K | 798 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Precigen
PGEN
|
3.2 M | $ 3.1 | -0.96 % | $ 758 M |  USA |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 19.57 | 1.77 % | $ 915 M | USA |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.33 | 0.76 % | $ 339 M |  Britain |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
233 K | $ 8.31 | 1.59 % | $ 111 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 47.09 | 1.42 % | $ 4.23 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
363 K | $ 4.53 | 5.1 % | $ 868 M | Canada |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | USA |
 |
CytomX Therapeutics
CTMX
|
1.2 M | $ 4.22 | -0.47 % | $ 582 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
6 K | - | -5.98 % | $ 34.1 M | USA |